ClinicalTrials.gg
Status unknownNCT04228393Updated Jan 14, 2020

The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China

A Phase 2/3 interventional study of 6-mercaptopurine and Standard treatment in Acute Lymphoblastic Leukemia, Pediatric, sponsored by Wei Zhao. Status unknown at 1 site in China. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2020-01-14.

Sponsored by Wei Zhao · Phase 2/3, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jan 2020), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China — 113 open to participants now, 125 under way, 11 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · China.

Planned enrollment
60th of 209
82 · median 45
Started
2020
with 19 others
Phase 2/3
11 of 232
4 open now
Registered
76th of 232
by date

Among the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China, this one is the 60th largest by planned enrollment of the 209 interventional ones that give a count, is one of 20 that started in 2020, is one of 11 in phase 2/3, and was the 76th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

113 of the 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China are open now. Recruiting first, the newest first:

108 more — sign in →

All 113 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in China, or all of them as a file.
02

Study summary

The purpose of this study was to assess the efficacy and safety of individualized treatment of 6-mercaptopurine (6-MP) in Chinese children with acute lymphoblastic leukemia, and to investigate the dose-concentration-response (DER) relationship between thiopurine metabolites and adverse events. The individualized administration of 6-MP was established in Chinese children with acute lymphoblastic leukemia.

Read the detailed description

To inflict minimal pain on the child contributing blood samples, opportunistic sampling design was chosen to collect pharmacokinetic samples.

03

Conditions studied

  • Acute Lymphoblastic Leukemia, Pediatric

Keywords

  • acute lymphoblastic leukemia
  • 6-mercaptopurine
  • children
  • individualized treatment
04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Confirmed diagnosis of acute lymphoblastic leukemia;
  2. Age 1-18y at time of initial diagnosis;
  3. (ECOG) performance status of 0-2
  4. signed by the patients parents or guardians before initiation of the study.

Exclusion criteria

Exclusion Criteria:

  1. Ph-positive ALL, matrue B-cell ALL, BC-CML;
  2. Secondary to immunodeficiency, second cancer;
  3. Abnormal liver and kidney function;
  4. Patients divided into intermediate or high risk groups according to the risk grouping criteria of the Chinese Children Cancer Group (CCCG) protocol-ALL 2015;
  5. Patients who enrolled in another clinical trial;
  6. Expected survival time less than the treatment cycle;
  7. Patients with other factors that researcher considers unsuitable for inclusion
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Active comparator
    Standard treatment regimen

    6-mercaptopurine was administered according to the Chinese Children Cancer Group (CCCG) protocol-ALL 2015.

    Drug: 6-mercaptopurine · Procedure: Standard treatment

  • Experimental
    Individualized treatment regimen

    6-mercaptopurine was administered on the basis of Chinese Children Cancer Group (CCCG) protocol-ALL 2015 combined with Clinical Pharmacogenetics Implementation Consortium (CPIC), genotypes and the concentrations of 6-TGN in red blood cells.

    Drug: 6-mercaptopurine · Procedure: Individualized treatment

Interventions

  • DrugMercaptopurineStudies of MercaptopurineMercaptopurine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    6-mercaptopurine was administered orally to patients once daily.

    Also known as: 6-MP

  • ProcedureStandard treatment

    The initial dose is 50mg/m2. The dose was adjusted according to white blood cells.

  • ProcedureIndividualized treatment

    The initial dose is determined according to the genotypes of patients combined with Clinical Pharmacogenetics Implementation Consortium (CPIC). The dose was adjusted according to white blood cells, genotypes and the concentrations of 6-TGN in red blood cells.

06

What researchers measure

Primary outcomes

  1. leukopenia

    Leukopenia was graded by common toxicity criteria as follows: Grade 3, 1.0-2.0 × 109/L, and Grade 4, \< 1.0 × 109/L.

    Time frame: 6 weeks

  2. thiopurine-induced leukopenia

    Resolution of leukopenia was determined after 6-MP dose reduction or discontinuation, both in the absence of other apparent causes for the leukopenia or its disappearance.

    Time frame: 6-weeks

Secondary outcomes

  1. hepatotoxicity

    Hepatotoxicity was defined as aspartate aminotransferase (AST) or alanine transaminase (ALT) levels 2-fold above the upper limit without cytolysis.

    Time frame: 6 weeks

  2. 6-thioguanine nucleotides (6-TGN) concentrations in erythrocytes.

    Peripheral blood samples were obtained from steady-state plasma concentrates by opportunistic sampling design.

    Time frame: 3 months

  3. 6-methylmercaptopurine nucleotides (6-MMPN) concentrations in erythrocytes.

    Peripheral blood samples were obtained from steady-state plasma concentrates by opportunistic sampling design.

    Time frame: 3 months

07

Study locations

1 site
  • State Key Laboratory of Experimental Haematology, Department of Paediatric Haematology, Institute of Haematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Tanjin, Tianjin 300020, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2020; primary completion for Dec 2022, 34 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2020
First posted
Jan 14, 2020
StartEst.
Feb 1, 2020
Primary completionEst.
Dec 31, 2022
CompletionEst.
Dec 31, 2022
Last update
Jan 14, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04228393
Lead sponsor
Wei Zhao
Responsible party
Wei Zhao (Professor; Head of department of clinical pharmacy and pharmacology, Shandong University) — Sponsor-investigator
First posted
Jan 14, 2020
Start date
Feb 1, 2020 (estimated)
Primary completion
Dec 31, 2022 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
Jan 14, 2020

Study contacts

Wei Zhao, Ph.D
Contact
zhao4wei2@hotmail.com
86053188383308
Yan H Shi, Ph.D
Contact
zhao4wei2@hotmail.com
86053188383308
Wei Zhao, Ph.D
principal investigator · Shandong University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion